相关实验视频

Updated: Sep 13, 2025

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

眼内注射和相关因素后眼内压力的即时和短期变化

Manabu Yamamoto¹, Kumiko Hirayama¹, Akika Kyo¹

¹Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.

Journal of clinical medicine

|July 29, 2025

概括

内注射的抗VEGF药物可能会导致暂时的眼内高压 (IOP),特别是在aflibercept. 诸如高基线内血压和青光眼病史等因素增加了这种风险,需要对患者进行仔细监测.

科学领域:

眼科医生眼科眼科
血管生物学血管生物学
药理学药理学是指药理学的学科.

背景情况:

抗血管内皮生长因子 (VEGF) 药物的静脉内注射 (IVI) 是各种眼部疾病的常见治疗方法.
注射后眼内压力 (IOP) 变化是已知的并发症,但其程度和相关因素需要进一步阐明.

研究的目的:

为了评估IVI抗VEGF药物的IVI后的即时和短期IOP变化.
为了确定与治疗后IOP升高相关的临床和程序因素.

主要方法:

从115名接受IVI与抗VEGF药物的患者118只眼睛的回顾性分析.
在注射前,注射后立即和注射后30分钟内心压力测量.
单变量和多变量回归分析以确定IOP升高的风险因素.

主要成果:

平均内血压从基线时的13.9 mmHg显著增加到注射后立即的39.2 mmHg,其中79.7%的眼睛显示内血压≥25 mmHg.
在注射后30分钟内,内压通常会降至17.7mmHg.
与其他药物相比,aflibercept (2 mg和8 mg) 的内血压增加更大;较高的基线内血压,绿眼病史和没有先前的玻璃切除术是危险因素.

结论:

过渡性,显著的内血压升高在IVI后很常见,但通常在30分钟内消失.
阿弗利塞普特的使用,高基线内血压,青光眼病史和没有先前的玻璃切除术都与更大的内血压升高有关.
对于高风险患者,建议对注射量进行仔细监测和考虑.

关键词:

一个自由的接受.抗血管内皮生长因子的抗血管内皮生长因子这就是brolucizumab.法里西马布 (法里西马布) 是一个法里西马布.眼内压力眼内压力内注射内注射内注射拉尼比祖马布拉尼尼比祖马布拉尼

更多相关视频

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

相关概念视频

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...